Latest Stories

BDSI Loses Bid to Extend Belbuca Injunction to New Alvogen Copy

A federal judge denied BioDelivery Sciences International Inc.’s attempt to use a 2022 patent-infringement judgment against Lotus Pharmaceutical Co.’s Alvogen units to stop a new generic version of the painkiller Belbuca, ruling BDSI used the wrong legal tool to enforce that injunction.

FROM ACROSS BLOOMBERG LAW

California BriefNew York BriefThe Brief – Top News of the Day From Bloomberg LawBusiness & Practice
  • California Brief
  • New York Brief
  • The Brief – Top News of the Day From Bloomberg Law
  • Business & Practice